Our data as well as those of others [19]–[22] suggest that the therapeutic armamentarium today available for human lymphomas might also include sorafenib mainly due to its antiangiogenic properties along with its antiproliferative and signaling inhibitory activities eventually associated with down modulation of Mcl-1 expression [31], [40], [41]. This evidence concerns the gene MCL1 and lymphoma.